Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus?: Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MVJZ | ISIN: FR0004056851 | Ticker-Symbol: AYJ
Tradegate
23.07.25 | 10:34
2,748 Euro
+5,53 % +0,144
Branche
Biotechnologie
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
VALNEVA SE Chart 1 Jahr
5-Tage-Chart
VALNEVA SE 5-Tage-Chart
RealtimeGeldBriefZeit
2,7542,76211:01
2,7502,76611:01
ACCESS Newswire
1.076 Leser
Artikel bewerten:
(2)

CliniOps, Inc.: Valneva Selects CliniOps as the Technology Partner for Multiple Post-Marketing Studies to Support the IXCHIQ Chikungunya Vaccination Program in Brazil

This collaboration underscores CliniOps' continued mission to transform clinical research through smart technologies, enabling equitable access, operational efficiency, and robust data quality, even in hard-to-reach geographies.

FREMONT, CA / ACCESS Newswire / June 19, 2025 / CliniOps, Inc., a leading provider of digital technology solutions for clinical trials, announced today that Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has selected CliniOps as the technology partner to support multiple Post-Marketing Surveillance (PMS) studies for Valneva's IXCHIQ® vaccine against the chikungunya virus (CHIKV).

Valneva Selects CliniOps as the Technology Partner

Valneva Selects CliniOps as the Technology Partner
Valneva Selects CliniOps as the Technology Partner for multiple PMS studies to Support the IXCHIQ® Chikungunya Vaccination Program

As part of the continued evaluation of IXCHIQ®'s safety and efficacy in real-world settings, Valneva will conduct several PMS studies.

  1. Pregnancy Surveillance Study: This prospective observational study aims to evaluate vaccine safety, through monitoring approximately 100 pregnant women exposed to IXCHIQ®.

  2. Safety Cohort Study: Designed to estimate the incidence of medically attended Adverse Events of Special Interest (AESIs), this study will enroll 5,000 adolescent and adult participants across 10 municipalities. It will also monitor for laboratory-confirmed CHIKV infection post-vaccination.

  3. Serosurvey Study: Aimed at assessing pre-exposure CHIKV prevalence in adolescents and adults, this study will include 5,000 participants, with point-of-care blood sample collection integrated into the workflow.

CliniOps' Unified Platform, featuring electronic data capture (EDC), eConsent, and ePRO, will enable participant enrollment, digital consent, data collection, and remote or in-person follow-up, ensuring flexibility and compliance across municipalities in urban and remote settings. The solution includes robust offline capabilities via mobile tablets, allowing site staff to reliably collect and synchronize data in areas with limited connectivity. CliniOps will work closely with P-95, Valneva's CRO partner, and also with Instituto Butantan, one of the world's largest biomedical research centers based in Sao Paulo, Brazil, to provide comprehensive training and ongoing support.

"These post-marketing studies support our ongoing efforts to further explore the real-world safety and effectiveness of IXCHIQ® and fulfill post-marketing surveillance requirements in populations exposed to CHIKV-endemic areas," said Dr. Juan Carlos Jaramillo, Chief Medical Officer at Valneva. "Our collaboration with CliniOps aligns with Valneva's strategic focus on driving more efficient, cost-effective, and high-quality clinical processes through the use of innovative technologies."

"This collaboration with Valneva highlights the growing global demand for agile, tech-enabled clinical trials," said Avik Pal, CEO, CliniOps. "We are certainly honored to bring our technology to bear on a public health initiative of this magnitude, supporting real-world data collection and post-approval monitoring for a vaccine with significant global impact."

Chikungunya virus (CHIKV) is spread to humans by the bite of an infected mosquito (Aedes aegypti and Aedes albopictus). Several significant CHIKV outbreaks are ongoing globally, including in Brazil where 71,578 CHIKV cases had been reported as of March 2025, the highest number globally for the year.

About Valneva

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. https://valneva.com

About CliniOps

CliniOps is a leading technology and data science company for the life sciences industry. CliniOps offers a Unified Platform Technology with multiple patents, for Reimagined Clinical Trials, with the ability to also support Hybrid and Decentralized Trials (Hybrid DCT). CliniOps is committed to making clinical trials accessible, inclusive, faster and efficient, by leveraging powerful technology with rich data-driven solution offerings. https://www.cliniops.com/

Contact Information

CliniOps Media
media@cliniops.com
+1 408.829.4677

.

SOURCE: CliniOps, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/valneva-selects-cliniops-as-the-technology-partner-for-multiple-post-1011366

© 2025 ACCESS Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.